Human Interleukin-8, CXCL8 ELISA Kit

Interleukin 8 (IL-8), also known as CXCL8, which is a chemokine with a defining CXC amino acid motif that was initially characterized for its leukocyte chemotactic activity, is now known to possess tumorigenic and proangiogenic properties as well. This chemokine is secreted by a variety of cell types including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, and various tumor cell lines in response to inflammatory stimuli (IL1, TNF, LPS, etc) . In human gliomas, IL-8 is expressed and secreted at high levels both in vitro and in vivo, and recent experiments suggest it is critical to glial tumor neovascularity and progression. Levels of IL-8 correlate with histologic grade in glial neoplasms, and the most malignant form, glioblastoma, shows the highest expression in pseudopalisading cells around necrosis, suggesting that hypoxia/anoxia may stimulate expression. Interleukin (IL) -8/CXCL8 is a potent neutrophil chemotactic factor. Accumulating evidence has demonstrated that various types of cells can produce a large amount of IL-8/CXCL8 in response to a wide variety of stimuli, including proinflammatory cytokines, microbes and their products, and environmental changes such as hypoxia, reperfusion, and hyperoxia. Numerous observations have established IL-8/CXCL8 as a key mediator in neutrophil-mediated acute inflammation due to its potent actions on neutrophils. However, several lines of evidence indicate that IL-8/CXCL8 has a wide range of actions on various types of cells, including lymphocytes, monocytes, endothelial cells, and fibroblasts, besides neutrophils. The discovery of these biological functions suggests that IL-8/CXCL8 has crucial roles in various pathological conditions such as chronic inflammation and cancer. IL-8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer. IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.

Concentration | O.D. | Average | Corrected ------------------------------------------ 240 pg/ml | 2.545 | 2.592 | 2.468 2.638 120 pg/ml | 1.259 | 1.241 | 1.117 1.222 60 pg/ml | 0.665 | 0.655 | 0.531 0.644 30 pg/ml | 0.382 | 0.386 | 0.262 0.389 15 pg/ml | 0.237 | 0.254 | 0.13 0.27 7.5 pg/ml | 0.189 | 0.186 | 0.062 0.182 3.75 pg/ml | 0.143 | 0.151 | 0.027 0.159 0 pg/ml | 0.117 | 0.124 | 0 0.13

Intra/Inter-Assay | Sample | n | Mean | Standard Deviation | CV% ---------------------------------------------------------------- Intra-assay | 1 | 20 | 18.3 | 1.2 | 6.7 Intra-assay | 2 | 20 | 41.5 | 2.2 | 5.2 Intra-assay | 3 | 20 | 138 | 7.8 | 5.6 Inter-assay | 1 | 20 | 18.2 | 1.4 | 7.9 Inter-assay | 2 | 20 | 41.6 | 3 | 7.2 Inter-assay | 3 | 20 | 139 | 7.2 | 5.2

Components | Quantity --------------------- Pre-coated ELISA Plate | 12 x 8 well strips x 1 Standard Solution | 0.2mL x 1 vail Dilution Buffer | 20mL x 1 vail Stop Solution | 6mL x 1 vail Substrate Solution A | 12mL x 1 vail Substrate Solution B | 12mL x 1 vail Wash Buffer Concentrate (25x) | 20mL x 1 vail Detection Antibody Concentrate | 0.6mL x 1 vail